EGFR and non-small cell lung carcinoma: A programmed death-ligand 1 (PD-L1) inhibitor, durvalumab, plus osimertinib in patients with EGFR-mutation positive NSCLC indicated a significantly high rate of lung toxicity, with an incidence of 22% (affecting five out of 23 patients).